Target Discovery Focus Tellic's automated extraction of genetic evidence and its knowledge graph position the company as a compelling partner for pharma and biotech teams focused on target identification, early validation, and evidence-driven BD. Sales opportunities include accelerating target discovery, shortening time-to-insights from literature, and strengthening decision support for clinical trial design and partner conversations.

Knowledge Graph Advantage The knowledge graph provides a centralized data layer that unifies disparate biomedical evidence, enabling integrated analytics, reproducible research workflows, and regulatory-ready reporting. This supports platform-level value for evidence synthesis, portfolio prioritization, and cross-functional collaboration with CROs and in-house analytics teams.

Pipeline Integration Tellic's tech stack, including SAS and Apache Airflow, signals strong data engineering capabilities and compatibility with enterprise data pipelines. This reduces integration risk for pharmaceutical customers and supports scalable ETL and ML workflows within existing environments.

Growth Upsell Potential With revenue in the low-to-mid single digits and a lean team, tellic has room to scale by expanding within current pharmaceutical and biotech customers to cover additional use cases such as target validation, protocol optimization, and BD insights. Consider pilots and expansion licenses to accelerate growth.

Regional Focus Headquartered in New York with proximity to major pharma and biotech activity, tellic can target US East Coast life sciences firms, CROs, and biotech startups seeking faster, evidence-driven decision-making enabled by automated genetic-evidence extraction and knowledge graphs.